New pill aims to keep AML away after transplant

NCT ID NCT06707493

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether the drug ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 75 adults with a specific IDH1 gene mutation will receive either ivosidenib or a placebo daily. The main goal is to see if the drug extends the time patients stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ivosidenib (a targeted pill that blocks a mutated IDH1 protein)
What this could lead to: If it works, this could help keep AML in remission longer after a stem cell transplant, reducing the chance of the cancer coming back.
What could go wrong: This is a mid-stage trial with only 75 people, so results may not be conclusive. Ivosidenib can cause side effects like heart rhythm changes or liver issues, and it may not prevent relapse for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML) HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IDH1 MUTATION

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States
Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States
Froedtert Hospital & the Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Huntsman Cancer Institute, University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Ohio State University Wexner Medical Center- James Cancer Hospital
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.